European regulators OK Alzheimer's treatment Leqembi after initial doubts
- The European Commission approved lecanemab to treat Alzheimer's, making it the first therapy to receive a marketing authorization in the EU.
- Lecanemab is the first treatment option in the EU that can slow the progression of early Alzheimer's disease.
- This decision applies to all 27 EU member states and Norway, Iceland, and Liechtenstein.
- Shares of Biogen rose about $2 to $119 in premarket trading following the approval.
124 Articles
124 Articles
European Regulators Ok Alzheimer’s Treatment Leqembi After Initial Doubts
HYANNIS – European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer and then reconsidered it. The infused treatment from Japanese drugmaker Eisai and Biogen received approval for patients in early stages of the fatal, mind-robbing disease. The decision applies to all 27 members of the […] The post European Regulators Ok Alzheimer’s Treatment Leqembi After Initi…


European regulators OK Alzheimer’s treatment Leqembi after initial doubts
European regulators have finally approved the Alzheimer's treatment Leqembi after an advisory committee initially rejected the drug last summer and then reconsidered it.
Coverage Details
Bias Distribution
- 44% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage